Malaria DNA vaccine - Okairos

Drug Profile

Malaria DNA vaccine - Okairos

Alternative Names: AdCh63 ME-TRAP - Okairos; ChAd63 ME-TRAP - Okairos; ME-TRAP malaria DNA vaccine - Okairos/University of Oxford; MVA ME-TRAP - Okairos

Latest Information Update: 09 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Okairos
  • Developer ReiThera; University of Oxford
  • Class Antimalarials; DNA vaccines; Parasitic vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 22 Mar 2017 University of Oxford plans a phase I trial for Malaria (Prevention) in United Kingdom (NCT03084289)
  • 09 Sep 2015 Phase-I/II development is ongoing in Burkina Faso
  • 09 Sep 2015 Phase-II development is ongoing in United Kingdom, Kenya and Senegal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top